INmune Bio (INMB) Competitors $1.89 -0.03 (-1.56%) Closing price 04:00 PM EasternExtended Trading$1.88 0.00 (-0.26%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock INMB vs. CHRS, BIOA, GNLX, CRBP, FBRX, DERM, FATE, PLX, IPHA, and TNXPShould you be buying INmune Bio stock or one of its competitors? The main competitors of INmune Bio include Coherus Oncology (CHRS), BioAge Labs (BIOA), Genelux (GNLX), Corbus Pharmaceuticals (CRBP), Forte Biosciences (FBRX), Journey Medical (DERM), Fate Therapeutics (FATE), Protalix BioTherapeutics (PLX), Innate Pharma (IPHA), and Tonix Pharmaceuticals (TNXP). These companies are all part of the "pharmaceutical products" industry. INmune Bio vs. Its Competitors Coherus Oncology BioAge Labs Genelux Corbus Pharmaceuticals Forte Biosciences Journey Medical Fate Therapeutics Protalix BioTherapeutics Innate Pharma Tonix Pharmaceuticals INmune Bio (NASDAQ:INMB) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk. Is INMB or CHRS more profitable? Coherus Oncology has a net margin of 125.90% compared to INmune Bio's net margin of 0.00%. Coherus Oncology's return on equity of 0.00% beat INmune Bio's return on equity.Company Net Margins Return on Equity Return on Assets INmune BioN/A -120.62% -92.94% Coherus Oncology 125.90%N/A -34.85% Which has more risk and volatility, INMB or CHRS? INmune Bio has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, Coherus Oncology has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Which has better valuation and earnings, INMB or CHRS? Coherus Oncology has higher revenue and earnings than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioINmune Bio$10K5,023.62-$42.08M-$2.48-0.76Coherus Oncology$266.96M0.76$28.51M$1.551.12 Does the media prefer INMB or CHRS? In the previous week, Coherus Oncology had 1 more articles in the media than INmune Bio. MarketBeat recorded 1 mentions for Coherus Oncology and 0 mentions for INmune Bio. Coherus Oncology's average media sentiment score of 0.67 beat INmune Bio's score of 0.00 indicating that Coherus Oncology is being referred to more favorably in the news media. Company Overall Sentiment INmune Bio Neutral Coherus Oncology Positive Do institutionals and insiders have more ownership in INMB or CHRS? 12.7% of INmune Bio shares are owned by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are owned by institutional investors. 21.0% of INmune Bio shares are owned by insiders. Comparatively, 8.1% of Coherus Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts recommend INMB or CHRS? INmune Bio currently has a consensus target price of $18.00, indicating a potential upside of 852.38%. Coherus Oncology has a consensus target price of $4.51, indicating a potential upside of 159.34%. Given INmune Bio's higher probable upside, equities research analysts clearly believe INmune Bio is more favorable than Coherus Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 2 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.29Coherus Oncology 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 SummaryCoherus Oncology beats INmune Bio on 12 of the 17 factors compared between the two stocks. Get INmune Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INMB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INMB vs. The Competition Export to ExcelMetricINmune BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$51.04M$3.48B$6.18B$10.69BDividend YieldN/A2.26%5.72%4.83%P/E Ratio-0.768.2420.7722.98Price / Sales5,023.62481.95579.80129.94Price / CashN/A47.5937.5161.65Price / Book1.3010.6612.476.59Net Income-$42.08M-$52.56M$3.32B$276.14M7 Day Performance1.07%4.97%1.87%0.01%1 Month Performance-0.53%16.48%8.40%3.60%1 Year Performance-63.51%14.95%63.49%32.76% INmune Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INMBINmune Bio1.7809 of 5 stars$1.89-1.6%$18.00+852.4%-62.4%$51.04M$10K-0.7610CHRSCoherus Oncology4.1942 of 5 stars$1.73+3.6%$4.51+160.8%+102.7%$194.10M$266.96M1.12330BIOABioAge LabsN/A$5.50+2.8%N/AN/A$191.80MN/A0.00N/AGNLXGenelux1.0966 of 5 stars$5.25+3.6%$20.33+287.3%+136.7%$191.51M$10K-6.1010News CoverageAnalyst ForecastGap UpCRBPCorbus Pharmaceuticals4.2375 of 5 stars$16.32+5.0%$45.43+178.4%-0.7%$190.45MN/A-3.4340Trending NewsAnalyst ForecastFBRXForte Biosciences2.8015 of 5 stars$14.75-3.4%$68.00+361.0%+157.7%$189.85MN/A-0.915Analyst DowngradeShort Interest ↑DERMJourney Medical2.0268 of 5 stars$7.00-2.9%$12.17+73.8%+18.1%$189.69M$56.13M-18.4290FATEFate Therapeutics4.1382 of 5 stars$1.39-15.0%$3.30+137.4%-52.3%$188.56M$13.63M-0.96550PLXProtalix BioTherapeutics2.1244 of 5 stars$2.45+3.8%$15.00+512.2%+96.3%$188.17M$61.95M-18.85200IPHAInnate Pharma2.0989 of 5 stars$1.93-4.9%$6.50+236.8%+4.2%$187.13M$21.77M0.00220TNXPTonix Pharmaceuticals2.8065 of 5 stars$20.06-5.3%$70.00+249.0%+10.2%$185.75M$10.09M-0.5150Short Interest ↑Gap Down Related Companies and Tools Related Companies Coherus Oncology Competitors BioAge Labs Competitors Genelux Competitors Corbus Pharmaceuticals Competitors Forte Biosciences Competitors Journey Medical Competitors Fate Therapeutics Competitors Protalix BioTherapeutics Competitors Innate Pharma Competitors Tonix Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INMB) was last updated on 10/21/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INmune Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share INmune Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INMB Stock Alerts